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ﻒﻴﺜﻜﺗﺽﺮﻐﺑﻦﻴﻟﻮﺴﻧﻹﺍﺀﺎﻄﻋﻹﺔﻔﺻﻭﻞﻀﻓﺃﺭﺎﻴﺘﺧﺍﻝﺍﺰﻳﻻ:ﺚﺤﺒﻟﺍﻑﺍﺪﻫﺃ
ﺓﺮﺜﻛﻦﻣﻢﻏﺮﻟﺍﻰﻠﻋ.ﻝﺪﺟﻊﺿﻮﻣﻲﻧﺎﺜﻟﺍﻉﻮﻨﻟﺍﻦﻣﻱﺮﻜﺴﻟﺍﺀﺍﺩﺕﻻﺎﺣﻲﻓﺝﻼﻌﻟﺍ
.ﻥﻵﺍﻰﺘﺣﺎﻬﺼﻴﺨﻠﺗﻢﺘﻳﻢﻟﺕﺎﻔﺻﻮﻟﺍﻚﻠﺘﻟﺔﻨﻣﻵﺍﻲﺣﺍﻮﻨﻟﺍﻰﻠﻋﺔﻟﺩﻷﺍﻥﺈﻓ٬ﺙﻮﺤﺒﻟﺍ
ﺩﺪﻌﺘﻣﻦﻴﻟﻮﺴﻧﻹﺍﺕﺎﻔﺻﻭﻦﻴﺑﻥﺎﻣﻷﺍﺕﺎﺟﺮﺨﻣﺔﻧﺭﺎﻘﻤﻟﺔﻳﺩﺮﺳﺔﻌﺟﺍﺮﻤﺑﺎﻨﻤﻗ
.ﻂﻠﺨﻟﺍﻖﺒﺴﻣﻦﻴﻟﻮﺴﻧﻹﺍﻰﻠﻋﺔﻳﻮﺘﺤﻤﻟﺍﺕﺎﻔﺻﻮﻟﺍﻭﺕﺎﻋﺮﺠﻟﺍ
ﺕﺎﺳﺍﺭﺪﻟﺍﻦﻋﺔﻴﻧﻭﺮﺘﻜﻟﻹﺍﺕﺎﻣﻮﻠﻌﻤﻟﺍﺪﻋﺍﻮﻗﻲﻓﺚﺤﺒﻟﺎﺑﺎﻨﻤﻗ:ﺚﺤﺒﻟﺍﻕﺮﻃ
ﻰﻠﻋﻑﺮﻌﺘﻠﻟ،ﻡ٤١٠٢ﺮﺒﻤﺴﻳﺩﻭﻡ٠٠٠٢ﺮﻳﺎﻨﻳﻦﻴﺑﺔﻳﺰﻴﻠﺠﻧﻹﺍﺔﻐﻠﻟﺎﺑﺓﺭﻮﺸﻨﻤﻟﺍ
ﻦﻴﺑﻦﻣ.ﻦﻴﻟﻮﺴﻧﻹﺍﻒﻴﺜﻜﺘﻟﺔﻔﻠﺘﺨﻤﻟﺍﺕﺎﻔﺻﻮﻟﺍﻦﻴﺑﺔﻧﺭﺎﻘﻤﻠﻟﺖﻳﺮﺟﺃﻲﺘﻟﺍﺕﺎﺳﺍﺭﺪﻟﺍ
ﻚﻠﺗﻥﺎﻣﺄﺑﺔﻘﻠﻌﺘﻤﻟﺍﺮﻴﻳﺎﻌﻤﻟﺍﺱﺎﻴﻗﺎﻬﻴﻓﻢﺗﻲﺘﻟﺍﺕﺎﺳﺍﺭﺪﻟﺍﺭﺎﻴﺘﺧﺍﻢﺗ٬ﺕﺎﺳﺍﺭﺪﻟﺍﻚﻠﺗ
ﺔﺳﺍﺭﺪﻠﻟﻂﻘﻓﻲﻧﺎﺜﻟﺍﻉﻮﻨﻟﺍﻦﻣﻱﺮﻜﺴﻟﺍﺀﺍﺩﻦﻣﻦﻴﻧﺎﻌﻳﻦﻳﺬﻟﺍﻦﻴﻐﻟﺎﺒﻟﺍﺪﻨﻋﺕﺎﻔﺻﻮﻟﺍ
ﺖﻠﺣﻭ،ﻦﻴﻨﺛﺇﻦﻴﺜﺣﺎﺑﻞﺒﻗﻦﻣﺔﺼﻠﺨﺘﺴﻤﻟﺍﺕﺎﻣﻮﻠﻌﻤﻟﺍﺔﻌﺟﺍﺮﻣﺖﻤﺗﻭ.ﺔﻴﻌﺟﺮﻤﻟﺍ
.ﺔﺸﻗﺎﻨﻤﻟﺎﺑﺮﻈﻨﻟﺍﺕﺎﻬﺟﻭﺕﺎﻓﻼﺘﺧﺍ
ﻲﺘﻟﺍﺕﺎﺳﺍﺭﺩ٠١ـﻟﺍﺚﺤﺒﻟﺍﻞﻤﺷ٬ﺖﺳﺭﺩﻲﺘﻟﺍﺔﺳﺍﺭﺩ٠٢ـﻟﺍﻦﻴﺑﻦﻣ:ﺞﺋﺎﺘﻨﻟﺍ
،ﺕﺎﻋﺮﺠﻟﺍﺩﺪﻌﺘﻣﻦﻴﻟﻮﺴﻧﻹﺍﺕﺎﻔﺻﻭﻦﻴﺑﻥﺎﻣﻷﺍﺕﺍﺮﺷﺆﻣﺹﺎﺧﻞﻜﺸﺑﺖﻧﺭﺎﻗ
ﻲﺘﻟﺍﻥﺎﻣﻷﺍﺕﺎﺟﺮﺨﻣﻦﻴﺑﻦﻣﻭ.ﻂﻠﺨﻟﺍﻖﺒﺴﻣﻦﻴﻟﻮﺴﻧﻹﺍﻰﻠﻋﺔﻳﻮﺘﺤﻤﻟﺍﺕﺎﻔﺻﻮﻟﺍﻭ
ﺎﻧﺪﺟﻭ٬ﻡﺎﻋﻞﻜﺸﺑ.ﺔﻴﺒﻠﺴﻟﺍﺙﺍﺪﺣﻷﺍﻭﻥﺯﻮﻟﺍﺓﺩﺎﻳﺯ٬ﻡﺪﻟﺍﺮﻜﺳﺽﺎﻔﺨﻧﺍﺎﻬﺳﺎﻴﻗﻢﺗ
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Abstract
Objectives: The best insulin regimen for the intensifica-
tion of insulin therapy in the management of type 2
diabetes mellitus (T2DM) remains controversial. Despite
substantial research, the body of evidence concerning the
safety aspects of such regimens has never been summa-
rized. We conducted a 14-year narrative review to
compare the safety outcomes of basal-bolus (BB) versus
premixed (PM) insulin regimens.
Methods: We searched electronic databases (PubMed,
Scopus, Proquest and Google Scholar) for English-
language studies published from January 2000 to
December 2014 to identify studies comparing insulin
intensification regimens. Only studies measuring they. This is an open access article under the CC BY-NC-ND license
.1016/j.jtumed.2015.04.001
N.I. Penwalla et al.258safety-related parameters of the specific regimens in
T2DM adult patients were selected for further review.
The extracted data were independently reviewed by two
researchers, and disagreements were resolved by
discussion.
Results: Of the 20 retrieved studies, we included 10
studies that specifically compared the safety parameters
of BB and PM Insulin regimens. Among the safety out-
comes measured were hypoglycaemia, weight gain and
adverse events. Broadly, we determined that the BB in-
sulin regimens were comparable to the PM insulin regi-
mens in terms of hypoglycaemia and adverse events. In
terms of weight gain, two of seven studies showed sig-
nificant weight gain in BB insulin regimen arms.
Conclusions: Generally, the safety profile of BB insulin
regimen was comparable to that of the PM insulin
regimen. None of the identified studies performed head-
to-head comparisons utilizing human insulin regimens
in both arms. Research comparing non-analogue insulin
regimens is warranted.
Keywords: Basal-bolus; Insulin intensification regimen; Pre-
mixed; Safety; Type 2 diabetes mellitus
 2015 The Authors.
Production and hosting by Elsevier Ltd on behalf of Taibah
University. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Diabetes mellitus is becoming one of the most highly
problematic health concerns of the 21st Century.1 Findings
from United Kingdom Prospective Diabetes Study
(UKPDS) revealed that affected Type 2 Diabetes mellitus
(T2DM) patients usually lose half of their b-cell functions
at the point of diagnosis, with a further annual decline of
5%.2 Most people need to begin treatment with oral anti-
diabetic agents combined with a lifestyle modification strat-
egy. In reality, normal glycaemic control is difficult to ach-
ieve with lifestyle changes alone.
In T2DM patients, with time, oral anti-diabetic agents
usually lose their effectiveness and patients need to seek
exogenous insulin therapy. Generally, implementation of a
successful insulin therapy requires three stages of treatment,
including insulin initiation, optimization and intensifica-
tion.3 For insulin intensification, when glycaemia is not
achieved after the initiation and optimization of insulin,
numerous recommendations exist in various guidelines for
the selection of a second-line insulin regimen.
Insulin therapy initiation with basal insulin or a premixed
insulin regimen, has been recommended in several local and
international practice guidelines as well as publications3e8
However, for insulin intensification, when normoglycaemia
is not achieved after insulin initiation, various
intensification recommendations exist, although there is no
clear strategy for the selection of the second-line insulinregimen.9 Among the recommendations for insulin
intensification, switching to an intensified premixed insulin
regimen,10e12 Basal-plus insulin regimen13e15 or Basal-
bolus insulin regimen12,16,17 may be included.
Multiple meta-analyses have been performed with regards
to insulin therapy comparisons. Lasserson et al., Giugliano
et al. and Vaag et al. conducted a meta-analysis to compare
and summarize the glucose control, clinical outcomes or
adverse events occurring with the use of various individual
insulin types, such as basal, biphasic and prandial insulin
therapy.6,18,19 Sumeet et al. otherwise performed a meta-
analysis on studies comparing conventional insulin versus
analogue insulin.20 Four trials reviewed in the previous meta-
analysis by Lasserson et al. (n ¼ 3/22)6 and Giugliano et al.
(n ¼ 2/16)19 were included in our review because they met
our review inclusion criteria.
To the best of our knowledge, there has been no published
literature review specifically summarising the safety related
outcomes of BB versus PM insulin intensification regimens.
Thus, this review attempts to provide a comparative over-
view of safety related outcomes involving the two insulin
intensification regimens.
Materials and Methods
We searched electronic databases (PubMed, Scopus,
Proquest and Google Scholar) from January 2000 to
December 2014 to identify studies comparing insulin inten-
sification regimens. We searched for English Language pa-
pers published from 2000 to 2014 with the following terms:
“INSULIN” AND “BASAL-BOLUS” or “PRANDIAL-
BASAL” AND “PREMIXED” or “BIPHASIC” AND
“COMPARISON” NOT “PAEDIATRIC.” The main in-
clusion criteria were studies comparing BB regimens versus
PM regimens alone in T2DM patients and measuring safety
related parameters. Any studies involving paediatric patients
were excluded. The data of each extracted safety parameter
was also independently reviewed by other researchers. Dis-
agreements during the data extraction were resolved by dis-
cussion between the researchers.
Results
Our initial search identified 20 papers,12,21e39 five studies
of which were excludes21,24,32,38,39 because they compared
regimens other than the two specific regimens, two were
excluded because they involved Type 1 Diabetes Mellitus
patients,22,34 two were excluded because there was no
safety related parameter measured in the study31,35 and one
was excluded due to different injection formulations used
for the BB regimen arm.37 The remaining ten selected
studies and their characteristics were analysed as shown in
Table 1.12,23,25e30,33,36 The safety parameters measured
within the studies were also analysed (Table 2).12,23,25e30,33,36
1. Hypoglycaemia
Most of the studies use different terminologies and defi-
nition for hypoglycaemia hypoglycaemia based on severity
and time period classifications (Table 3).12,23,25,27,28,30,33,36
Hypoglycaemia was defined by Rosenstock et al. as an
Table 1: Characteristics of the selected studies.
Source Study
duration
(Week)
Study sites Number of study
subjects, n
Study Arm 1 Study Arm 2
(Ligthelm et al., 2006)28 16 Multicentre (Germany, United Kingdom,
France, Spain, Poland, the Netherlands,
Sweden, Croatia, Romania, Russia,
Hong Kong, Singapore and Malaysia)
394 Human isophane insulin (NPH)
and insulin aspart (IAsp) thrice
daily
Biphasic insulin aspart thrice daily
meal-.BIAsp 70 (BMI 30) or
BIAsp 50 (BMI>30) with breakfast
and lunch and BIAsp 30 with
dinner
(Rosenstock et al., 2008)12 24 Multicentre (United states and
Puerto Rico)
374 Glargine at bedtime and
mealtime lispro
Humalog Mix 50/50 thrice daily
with meals. Humalog Mix 50/50
replaceable with Humalog Mix
75/25 at the evening meal if the
fasting plasma glucose target
unachievable
(Masuda et al., 2008)29 12 Single-centre study (Tokyo, Japan) 28 NPH insulin at bedtime and
preprandial insulin lispro
Lispro Mix 50/50 twice daily
(Liebl et al., 2009)27 26 Multicentre (Austria, Germany and
Switzerland)
719 Insulin detemir once daily and
insulin aspart mealtimes
Biphasic insulin aspart (30/70)
twice daily
(Sakamoto et al., 2010)33 8 Single-centre study (Tokyo, Japan) 37 NPH insulin at bedtime and
preprandial insulin lispro or
insulin aspart.
Twice daily of 50/50 premixed
insulin lispro or 30/70 premixed
insulin aspart.
(Fritsche, Larbig, Owens,
& Ha¨ring, 2010)23
52 Multicentre (Europe and Australia) 310 Insulin glargine and premeal
glulisine
Biphasic human insulin (30/70)
or BIAsp 70/30 twice daily
(Miser et al., 2010)30 24 Multicentre (Argentina, Australia,
Brazil, Canada, Greece, Iran, India,
Netherlands, Romania, Spain, and
United States.)
399 (intensification
arm A),
345 (intensification
arm B)
Glargine insulin once daily and
mealtime insulin lispro thrice
daily
Lispro Mix 50/50 thrice daily
or Lispro Mix 75/25 twice daily
(Levin et al., 2011)26 36 Multicentre (United States) 197 Insulin glargine and premeal
glulisine
Lispro mix 75/25 or Biasp 70/30
(frequency undefined)
(Hsia et al., 2011)25 <1 Single-centre study (Colorado,
United States)
22 Glargine insulin once daily and
mealtime insulin lispro thrice
daily
Biphasic human insulin (30/70)
twice daily or thrice daily
(Walia, Upreti, Bhansali,
Dutta, & Shanmugasundar,
2012)36
12 Single-centre study (Chandigarh,
India)
50 Basal detemir once or twice daily
and bolus aspart
Biphasic human insulin (30/70)
thrice daily
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Table 2: Safety parameters measured from the selected studies.
No. Source Safety parameters measured
Hypoglycaemia Weight Gain Adverse Events
1 (Ligthelm et al., 2006)28   
2 (Rosenstock et al., 2008)12   
3 (Masuda et al., 2008)29 
4 (Liebl et al., 2009)27  
5 (Sakamoto et al., 2010)33 
6 (Fritsche et al., 2010)23   
7 (Miser et al., 2010)30   
8 (Levin et al., 2011)26  
9 (Hsia et al., 2011)25 
10 (Walia, Upreti, Bhansali,
Dutta, & Shanmugasundar,
2012)36
  
N.I. Penwalla et al.260episode with classic cognitive and/or adrenergic signs that is
confirmed with or without the plasma glucose (PG) levels.12
However, Miser et al. and Hsia et al. defined hypoglycaemia
as having a PG level of 70 mg/dL (3.9 mmol/l) or
experiencing symptoms typically related with
hypoglycaemia.25,30 All ten selected studies assessed
hypoglycaemia as a safety comparison parameter.12,23,25e
30,33,36 In all of the studies, there was no statistical
significant difference in terms of the number or proportion
(percentage) of subjects experiencing hypoglycaemia
episodes, number of hypoglycaemic episodes and incidence
rate of hypoglycaemia (events/subject/week) between
patients who were on the BB or PM regimen
(Table 4).12,23,25e30,33,36 However, a sub-hoc analysis of the
total minor hypoglycaemia events in one of the studies byTable 3: Classification of the hypoglycaemia terms from the selected
Classification factor Term used Defini
Severity Self-treatable
(Minor)
Asymptomatic No s
level 
Amo
asymp
Symptomatic  Sym
leve
72
70
60
56
<56
50
 Not
 Am
sym
hyp
Self-untreatable
(Major or Severe)
 Ass
and
i.v.
Time periods Nocturnal  Epis
time
 Epis
 Epis
insu
Daytime  EpisWalia et al. showed a significantly higher number of
documented symptomatic hypoglycaemic episodes in the
BB regimen arm.362. Weight gain
A change in weight from the baseline to the endpoint was
measured in seven out of ten studies analysed. All seven
studies showed that there was an increase in weight in both
groups (Table 5).12,23,26e28,30,36 Two out of seven studies
showed that the BB arm showed statistically significant
weight gain compared to the PM arm,23,26 while the
remaining five studies indicated that the increase was
comparable across arms.12,27,28,30,36studies.
tions
ymptoms of hypoglycaemia but PG
70 mg/dl (3.9 mmol/l)36
ng minor hypoglycaemia subcategorization:-
tomatic hypoglycaemia36
ptoms of hypoglycaemia based on plasma glucose
ls either
mg/dl (4 mmol/l)12
mg/dl (3.9 mmol/l)25,30,
mg/dl (3.3 mmol/l)12 or
mg/dl (3.1 mmol/L)28
mg/dl (<3.1 mmol/L)27,28
mg/dl (2.8 mmol/l)12,33
requiring assistance by another individual.
ong minor hypoglycaemia subcategorization:- documented
ptomatic hypoglycaemia, probable symptomatic
oglycaemia and relative hypoglycaemia36
ociated with plasma glucose level of <36 mg/dl (2.0 mmol/l)
patient require third-party help, including oral carbohydrate,
glucose or i.m. glucagon.12,23,27,28,30,33
odes occurring between 00:00 and 06:00, inclusive of both
s28
odes occurring between 22:00 and 06:00, inclusive of both times36
odes occurring after bedtime and before the morning meal or
lin dose30
odes occurring outside the 00:00 and 06:00 time interval28
Safety of basal-bolus versus premixed insulin intensification regimens 2613. Adverse events
Adverse events are defined as any unfavourable and un-
intentional sign, symptom, syndrome or illness that occurs orTable 4: Hypoglycaemia related findings from the selected studies.
Hypoglycaemic
terms
Variable Source
Minor Number and percentage
of subjects experiencing
hypoglycaemic episodes,
N (%)
(Walia, Upreti,
Shanmugasund
(Fritsche et al.,
(Rosenstock et
(Levin et al., 20
Number of hypoglycaemic
episodes, E
(Fritsche et al.,
(Hsia et al., 201
(Liebl et al., 20
(Walia, Upreti,
Shanmugasund
Incidence rate, (events/
subject/week)
(Fritsche et al.,
(Rosenstock et
(Walia, Upreti,
Shanmugasund
(Liebl et al., 20
(Masuda et al.,
Major Number and percentage
of subjects experiencing
hypoglycaemic episodes,
N (%)
(Ligthelm et al
(Rosenstock et
(Fritsche et al.,
(Walia, Upreti,
Shanmugasund
(Miser et al., 20
(Miser et al., 20
(Liebl et al., 20
Number of hypoglycaemic
episodes, E
(Miser et al., 20
(Miser et al., 20
(Ligthelm et al
(Fritsche et al.,
(Walia, Upreti,
Shanmugasund
(Sakamoto et a
Incidence Rate, (events/
subject/week)
(Rosenstock et
(Fritsche et al.,
(Walia, Upreti,
Shanmugasund
Nocturnal Number and percentage
of subjects experiencing
hypoglycaemic episodes,
N (%)
(Liebl et al., 20
(Rosenstock et
(Fritsche et al.,
(Walia, Upreti,
Shanmugasund
Number of hypoglycaemic
episodes, E
(Fritsche et al.,
(Walia, Upreti,
Shanmugasund
Incidence Rate, (events/
subject/week)
(Rosenstock et
(Fritsche et al.,
(Walia, Upreti,
Shanmugasund
(Miser et al., 20
(Miser et al., 20
n.a: not available in the literature; n.s: not statistically significant. The
ported by the original authors. * A p value of <0.05 was chosen as the
a Findings based on PG level < 72 mg/dl (4 mmol/l).
b Findings based on PG level < 70 mg/dl (3.9 mmol/l).
c Converted from literature to Incidence Rate, (events/subject/week)
d Assumed symptomatic hypoglycaemia as not specified in the literat
e Arm A: premixed regimen used is Lispro Mix 75/25 BID.
f Arm B: premixed regimen used is LM50/50 TID.worsens during the study.23 However, Serious Adverse
Events (SAEs) is defined as an occurrence at any dose,
resulting in mortality, persistent or significant incapability,
congenital defect, life-harming experience, hospitalization,BB Arm PM Arm p-Value*
Bhansali, Dutta,
ar, et al., 2012)36
15 (44.0) 20 (80.0) n.a
2010)23 106(69.3) 101 (64.3) 0.298
al., 2008)12,a 165 (88.2) 165 (88.2) 1.000
11)26 n.a (36.0) n.a (42.0) 0.370
2010)23 1369 1987 n.a
1)25,b 5 3 0.050
09)27 11 0 n.a
Bhansali, Dutta,
ar, et al., 2012)36
37 53 n.a
2010)23 0.19 0.26 0.236
al., 2008)12,a 0.86 0.89 0.747
Bhansali, Dutta,
ar, et al., 2012)36
0.12 0.18 n.a
09)27 0.04 0.04 0.837
2008)29,c,d 0.32 0.26 n.s
., 2006)28 2 (1.0) 6 (3.1) n.s
al., 2008)12 4 (2.1) 6(3.2) 0.751
2010)23 12(7.8) 12(7.6) 0.946
Bhansali, Dutta,
ar, et al., 2012)36
3(12.0) 2(8.0) 0.520
10)30,e n.a (0) n.a(1.0) 0.166
10)30,f n.a (0) n.a(1.0) 0.188
09)27 n.a (0.9) n.a (0) n.a
10)30,e 0 2 0.166
10)30,f 0 2 0.188
., 2006)28 2 7 n.s
2010)23 18 30 n.a
Bhansali, Dutta,
ar, et al., 2012)36
3 2 n.a
l., 2010)33 0 0 n.a
al., 2008)12 0.001 0.002 0.266
2010)23 0.002 0.004 0.234
Bhansali, Dutta,
ar, et al., 2012)36
0.010 0.010 n.a
09)27 40 (7.4) 13(7.3) n.s
al., 2008)12 110 (58.8) 109 (58.2) 1.000
2010)23 60 (39.2) 68 (43.3) 0.477
Bhansali, Dutta,
ar, et al., 2012)36
8 (32.0) 12(48.0) n.a
2010)23 281 329 n.a
Bhansali, Dutta,
ar, et al., 2012)36
13 15 n.a
al., 2008)12,c 0.120 0.090 0.139
2010)23 0.040 0.050 0.966
Bhansali, Dutta,
ar, et al., 2012)36
0.040 0.050 n.a
10)30,e 0.060 0.050 0.657
10)30,f 0.050 0.050 0.949
data presented in this table were extracted from the articles as re-
level of significance.
.
ure.
Table 5: Summary of weight change findings from the selected studies.
Source Mean weight changes, kga *p-Value
PM regimen BB regimen
(Rosenstock et al., 2008)12 4.0  4.2 4.5  4.4 0.22
(Liebl et al., 2009)27 2.1  4.0 2.4  4.1 >0.05
(Miser et al., 2010)30 0.9  3.4b 1.4  3.0b 0.10
0.9  3.5c 0.6  2.9c 0.35
(Walia, Upreti, Bhansali, Dutta,
Shanmugasundar, et al., 2012)36
1.5  0.3d 1.4  0.3d >0.05
(Ligthelm et al., 2006)28 2.0e 2.0e >0.05
(Levin et al., 2011)26 6.3(13.9 lbs) e,f 3.1(6.9 lbs)e,f 0.03
(Fritsche et al., 2010)23 3.6  4.0 2.2  4.5 0.01
The data presented in the table were extracted from the articles as reported by the original authors. * A p value of <0.05 was chosen as the
level of significance.
a Data were reported as the mean  s.d, unless otherwise specified.
b Arm A: premixed regimen used is Lispro Mix 75/25 BID.
c Arm B: premixed regimen used is LM50/50 TID.
d Data reported as the mean  Standard Error of the Mean (SEM).
e Data for the standard deviation not available.
f Data converted from lbs to kg, conversion Rate 1 kg ¼ 2.2 lbs.
N.I. Penwalla et al.262prolongation of hospitalization or any other event deemed
serious by the researcher.23,30 Five studies reported an
incidence of adverse events while on the insulin
regimens.12,23,28,30,36 The incidence of adverse events was
also evaluated via observation by the investigators or
reports by the patients at each point of investigator-patient
contact.23,28
Adverse events reported in the literature were categorized
into three categories: overall, mild or serious
(Table 6).12,23,28,30,36 In terms of the overall adverse events,
Lighthelm et al. documented that the most frequent
adverse events were headache, rhinopharyngitis and
hypertension.28 In addition, Rosenstock et al. reported that
one BB arm patient had to be withdrawn from the study
due to oedema, shortness of breath and elevated creatinine
levels.12 In terms of SAEs, Rosenstock et al. reported that
one patient each from the PM and BB arm had to be
withdrawn from the study due to acute respiratory failure
and myocardial infarction, respectively.12 All five studies
demonstrated that there was no statistical significant
difference between the PM and BB arm in terms of adverse
events.12,23,28,30,36
Mortality was also reported in the studies as one of the
SAEs. In one of the studies, there was one death reported
that was unrelated to the trial product in which an elderly
patient died seven days post-PM regimen initiation due to
myocardial infarction.28 However, another study reported
two deaths overall, one in each arm, which were both
unrelated to the trial product; the cause of death not
described in the literature.23 Furthermore, one death in the
BB arm caused by cardiovascular related SAEs was
reported in another study.30Discussion
This review observed that the key safety parameters
measured in previous comparative studies on the safety of
different insulin intensification regimens included hypo-
glycaemia, weight gain and adverse events.Our review observed that hypoglycaemia was defined
differently using specific terminologies in the selected
studies.12,23,25,27,28,30,33,36 Moreover, we found that all ten
studies reported no statistical significant difference in terms
of hypoglycaemia related measurements, such as the
number of subjects experiencing hypoglycaemia episodes,
hypoglycaemic episodes and incidence rate of
hypoglycaemia in patients utilizing either the BB or PM
insulin regimen.12,23,25e30,33,36 However, a study by Walia
et al. further examined and categorized the incidence of
hypoglycaemia into major and minor hypoglycaemia.
Minor hypoglycaemia was further sub-divided into four
subcategories: documented symptomatic hypoglycaemia,
probable symptomatic hypoglycaemia, asymptomatic
hypoglycaemia and relative hypoglycaemia. A sub-hoc
analysis of the minor hypoglycaemia events in this study
showed a statistically significantly number of documented
symptomatic hypoglycaemic episodes in the BB regimen arm
compared to the PM regimen arm.36 The general finding
from our review lends support to two previous meta-
analyses that demonstrated that the overall rate or inci-
dence of hypoglycaemia among the two different regimens
was comparable.6,19
Excessive weight gain may result in cardiovascular
complications, and via psychological barriers and adherence
hindering effects, it may lead to an increased risk of diabetic
morbidity and mortality.40 Two out of seven studies showed
that the BB arm had a statistically significant weight gain
compared to the PM arm,24,27 while the remaining five
studies showed that the increase was comparable across
arms.12,27,28,30,36 The reason for this discrepancy is
unclear, but it may be due to the relatively smaller sample
size and partly due to the use of only a twice daily
premixed insulin regimen in these two studies and not a
thrice daily regimen as described in the other analysed
studies. Fritsche et al. further demonstrated that weight
gain across the arm may not be considered clinically
significant, although there was statistically significant
difference in weight gained among their study population,
as this increment was within the normal range for weight
Table 6: Adverse events data from the selected studies.
Category Study Adverse events
Overall Mild Serious
BB PM BB PM BB PM
Number of patients,
n (%), Number
of Events [n]
(Ligthelm et al., 2006)28 110 (55.6%), [290] 110 (56.1%), [253] [253] [223] 9 [10] 7 [8]
(Fritsche et al., 2010)23 90 (58.8%), [328] 95 (60.5%), [371] 26 24
(Miser et al., 2010)30,a 20 15
(Walia, Upreti, Bhansali,
Dutta, Shanmugasundar,
et al., 2012)36
26[53]c 34[70]c 3b 2b
(Rosenstock et al., 2008)12 [13] [9]
No of events
unrelated to
trial Product[n]
(Ligthelm et al., 2006)28 [190] [175] [8] [6]
(Rosenstock et al., 2008)12 [12] [9]
No. of patient
withdrawals due
to adverse event, n
(Ligthelm et al., 2006)28 3 4
(Fritsche et al., 2010)23 7 3
(Miser et al., 2010)30,a 4 4
(Rosenstock et al., 2008)12 1 0 1 1
No. of adverse events
by the organ system,
[n]:
 Cardiovascular event
(Fritsche et al., 2010)23 [5] [7]
(Miser et al., 2010)30,a [11] [7]
 Nervous system
disorders
(Fritsche et al., 2010)23 [2] [0]
 Metabolism and
nutrition disorders
or Endocrine
(Fritsche et al., 2010)23 [4] [1]
(Miser et al., 2010)30,a [1] [1]
 Other (Fritsche et al., 2010)23 [18] [23]
(Miser et al., 2010)30,a [20] [7]
The data presented in the table were extracted from the articles as reported by the original authors.
Shaded area indicates data not available from the literature.
a Combined total of both Intensification Arm A&B.
b Data based on the occurrence of major hypoglycaemia.
c Data based on overall hypoglycaemia (minor, major and nocturnal).
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body weight.23,41
The next safety parameter of concern is adverse events.
In our review, we found only two studies defined adverse
events and SAEs.23,30 Five studies measured this parameter,
although none of the studies showed any statistical
significant difference between the BB and PM arms. The
findings from our review were consistent with those
reported by previous meta-analyses, which concluded that
the incidence of adverse events, such as severe hypo-
glycaemia or general hypoglycaemia were similar across the
two insulin arms.6,19 Four trials reviewed in the two
previous meta-analysis by Lasserson et al. (n ¼ 3/
22)12,28,31 and Giugliano et al. (n ¼ 2/16)12,27 were included
in our review because they met our review inclusion criteria.
Various adverse events and serious adverse events were
reported in the studies analysed. This narrative review and
previous meta-analysis together highlights that incidence
of hypoglycaemia is a serious adverse event of insulin
therapy and consideration must be taken when selecting
different types of insulin regimens.
From this 14-year literature review analysis, we found
that none of the studies compared safety parameters for the
non-analogue insulin regimen in both arms. All of the studies
found thus far have at least one analogue component in at
least one of its arms. In developing countries, the use ofanalogue insulin, rapid or long-acting in comparison to hu-
man insulin, is very low, because cost is a concern in the
public healthcare setting.7,42 Thus, because human insulin is
still the mainstay of therapy in developing countries,
conducting future insulin comparative studies utilizing
human insulin regimens is crucial to measure for any
differences in the findings.
Limitations
Nevertheless, this review has some limitations. The
studies included in this review were all in the English lan-
guage, and thus, some studies in other languages may have
been missed. In addition, in this review, each individual study
has its varied inclusion and exclusion criteria as well as
different dosing and frequencies of insulin utilized in each
study arm.
Conclusion
Our review on the safety comparison of insulin intensifi-
cation regimens indicated that the BB and PM insulin regi-
mens are equally safe in terms of the rate of hypoglycaemia
and adverse events. Only weight gain was observed to have a
statistically significant difference among patients in the BB
N.I. Penwalla et al.264arm in two of the studies. Thus, our review concluded that
the BB and PM regimens are comparably safe for use in
T2DM patients. Moreover, we found that all of the studies in
our review involved analogue insulin regimens. Previous
studies have shown that human insulin is still highly utilized
in public healthcare settings in developing countries due to its
relatively lower cost compared to analogue insulins. Thus,
further research comparing these two intensification regi-
mens, but using human insulin, warrants future analysis to
measure any difference in the findings.
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